Note 13 - Subsequent Event

6 Months Ended

Jun. 30, 2019

Notes to Financial Statements

Subsequent Events [Text Block]

13. Subsequent Event

On

July 8, 2019,

we announced that we exercised our option to acquire the remaining

56%

of the outstanding shares of privately held SAVSU Technologies that we do

not

currently own in exchange for

1.1

million shares of BioLife common stock. The acquisition closed on

August 7, 2019.

Due to the limited time since the acquisition date and the effort required to assess the fair value of assets acquired and liabilities assumed, the initial accounting for the business combination is incomplete at the time of this filing. As a result, the Company is unable to provide the amounts recognized for the major classes of assets acquired and liabilities assumed, acquisition contingencies and goodwill. Also, the Company is unable to provide pro forma revenues and earnings of the combined entity. This information is expected to be included in the Company's Quarterly Report on Form

10

-Q for the quarter ended

September 30, 2019.